Clinical trialNCT07007273RecruitingPhase 2Interventional

Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma

SponsorH. Lee Moffitt Cancer Center and Research InstituteEnrollment17Cutaneous Sarcoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a single arm, open-label phase II study to assess the efficacy of single agent pembrolizumab for the treatment of advanced cutaneous sarcomas. Adult patients ≥18 years old who have been diagnosed with an advanced cutaneous sarcoma without regard to race, ethnicity, and/or gender. Approximately N=17 patients are planned to be enrolled. Pembrolizumab 200 mg will be administered as 30-minute IV infusion every 21 days (3 weeks).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Andrew Brohl, MD
Moffitt Cancer Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Moffitt Cancer Center
Tampa, Florida, United States
Andrew Brohl, MD →Isabel Canizares, RN, BAS, OCNJonathan Metts, MDLeah Clark, ARNPMauricio Silva Almeida Ribeiro, MDMichael Shafique, MDMihaela Druta, MDSara McElroy, DPN, ARNP, FNP-BC, CPN
Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Not, yet, recruiting
Md Anderson Cancer Center
Houston, Texas, United States
Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pembrolizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 20 Jun 2025
Primary completion: 31 Jul 2030
Completion: 31 Jul 2030
Last update posted: 1 Apr 2026
Registered enrollment: 17
Registry id: NCT07007273

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.